29 results
Here is a quick guide on the common direct-acting antivirals (DAAs) for chronic hepatitis C virus
direct-acting antivirals ... (DAAs) for chronic ... #DAAs #Antivirals ... HepatitisC #Management #Pharmacology
Guide to Treatment of Hepatitis C with Direct Acting Antivirals.

Here is a pocket guide to initial
Direct Acting Antivirals ... treatment of HCV with DAAs ... #Management #Pharmacology ... HepatitisC #HCV #DAA ... #DirectActing #Antivirals
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Recommendations for Preventing ... doses for 30–60 days ... PO for 90–120 days ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... day for 10–14 days ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... Penicilliosis #IDSA #Prevention ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Recommendations for Preventing ... Preventing First ... HumanPapillomavirus #IDSA #Prevention ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
., 4 mg/kg on days ... mg/kg every 21 days ... Leishmaniasis #Prevention ... opportunistic #infections #HIVAIDS ... #pharmacology
This is an overview of the 3 main drug classes used to treat Hepatitis C

The new
Direct-Acting Antivirals ... Nomenclature #Classes #DAAs ... #Pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Therapy: 7–14 days ... Therapy: 14–21 days ... mucosal #IDSA #Prevention ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
Recommendations for Preventing ... ) in HIV-AIDS Preventing ... lifethreatening disease • Antiviral ... opportunistic #infections #HIVAIDS ... #pharmacology